A panel of 20 recombinant Fab fragments reactive with the surface glycoprotein gpl20 of human type 1 immunodeficiency virus (HIV-1) were examined for their ability to neutralize MN and hUB strains of the virus. Neutralization was determined as the ability of the Fab fragments to inhibit infection as measured in both a p24 ELISA and a syncytium-formation assay. One group of closely sequencerelated Fab fragments was found to neutralize virus in both assays with a 50% neutralization titer at -1 ,ug/ml. Another
tion was determined as the ability of the Fab fragments to inhibit infection as measured in both a p24 ELISA and a syncytium-formation assay. One group of closely sequencerelated Fab fragments was found to neutralize virus in both assays with a 50% neutralization titer at -1 ,ug/ml. Another Fab neutralized in the p24 ELISA but not in the syncytium assay. The other Fab fragments showed weak or no neutralizing ability. The results imply that virion aggregation or crosslinking of gp120 molecules on the virion surface is not an absolute requirement for HIV-1 neutralization. Further, all of the Fab fragments were shown to be competitive with soluble CD4 for binding to gpl20 and yet few neutralized the virus effectively, implying that the mechanism of neutralization in this case may not involve receptor blocking. The observation of a preponderance ofhigh-affminty Fab fragments with poor or no neutralizing ability could have implications for vaccine strategies.
The binding of antibodies to viruses can result in loss of infectivity or neutralization and, although antibodies are not the only defense mechanism against viruses, it is widely accepted that antibodies have an important role to play (reviewed in ref. 1) . However, understanding of the molecular principles underlying antibody neutralization is limited and lags behind that of the other effector functions of antibody (2) . Such understanding is required for the rational design of vaccines and for the most effective use of passive immunization for prophylaxis or therapy. This is particularly urgent for the human immunodeficiency viruses (HIVs).
A number of studies have led to the general conclusion that viruses are neutralized by more than one mechanism and the one employed will depend on factors such as the nature of the virus, the epitope recognized, the isotype of the antibody, the cell receptor used for viral entry, and the virus/antibody ratio (1) . The principal mechanisms of neutralization can be considered as (i) aggregation of virions, (ii) inhibition of attachment of virus to cell receptor, and (iii) inhibition of events following attachment, such as fusion of viral and cellular membranes and secondary uncoating ofthe virion. One ofthe important features of the third mechanism is that it may require far less than the approximately stoichiometric amounts of antibody expected for the first two mechanisms, since occupation of a small number of critical sites on the virion may be sufficient for neutralization. For instance, it has been shown that neutralization of the influenza A virion obeys single-hit kinetics (3) .
Intensive studies have been carried out on antibody neutralization of HIV-1 (reviewed in ref. 4) . Most have focused on a single linear epitope in the third hypervariable domain of the viral envelope glycoprotein gpl20 known as the V3 loop. Antibodies to this loop are suggested to neutralize by inhibiting fusion of viral and cell membranes. Binding to the loop resulting in neutralization can occur before virus-cell interaction (M. Merges and P. L. N., unpublished work) or after binding of gpl20 to CD4 (5) (6) (7) (8) . Features of the V3 loop are sequence variability within the loop (9-11) and sensitivity of neutralizing antibodies against the loop to sequence variations outside the loop (4, (11) (12) (13) . Hence anti-V3 loop antibodies are often strain-specific and mutations in the loop in vivo may provide a mechanism for viral escape from antibody neutralization. Recently considerable interest has focused on antibodies capable of blocking CD4 binding to gpl20-these are loosely described as "antibodies to the CD4 binding region. " A number ofgroups have described these antibodies as (a) reacting with conformational (i.e., nonlinear) epitopes, (b) reacting with a wide range of virus isolates, and (c) being the predominant neutralizing antibodies in humans after longer periods of infection (14) (15) (16) (17) (18) (19) . Neutralizing antibodies of this type would appear to present a promising target for potential therapeutics. The mechanism(s) of neutralization of these antibodies is unknown, although there is some indication that they may not act by blocking the attachment of virus, since a number of mouse monoclonal antibodies inhibiting CD4 binding to gpl20 are either nonneutralizing (20) or only weakly neutralizing (21) .
The generation of human monoclonal antibodies against the envelope of HIV-1 (22) through the use of combinatorial libraries allows another approach to the problem of neutralization. Given the lack of a three-dimensional structure for gpl20 and the complexity of the virus, the approach seeks to explore neutralization at the molecular level through the behavior ofrelated antibodies. This is possible because (i) the combinatorial approach allows the rapid generation of large numbers of human antibodies, (ii) the antibodies (Fab fragments) are expressed in Escherichia coli and can readily be sequenced, and (iii) antibodies have similar sequences and common structural motifs, allowing functional differences to be meaningfully correlated with primary structure.
Here we describe neutralization studies on 20 recombinant human Fab fragments against gpl20, all of which are straincrossreactive and inhibited by CD4 from binding to gpl20.
Abbreviations: HIV, human immunodeficiency virus; PBMC, peripheral blood mononuclear cell.
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We show that neutralization is not effected by virus aggregation or crosslinking of gpl20 molecules on the virion surface and is not correlated with blocking of the interaction between soluble CD4 and recombinant gpl20.
MATERIALS AND METHODS
Generation of Soluble Fab Fragments Reactive with gpl20. The preparation of RNA from the bone marrow lymphocytes of an HIV-1-seropositive individual, construction of an IgGl(K) Fab library on the surface of phage by use of the pComb3 system, panning of the library against recombinant gpl20 from the IIIB strain of HIV-1, and selection of phagemids expressing soluble Fab fragments that react with gpl20 in ELISA assays are described in ref. 22 , and the methodology is described in refs 22-24.
Competition ELISAs. Relative Fab binding affinities were estimated by competition, for Fab fragments, of free gpl20 with gp120 coated on ELISA wells (22, 25) . The ability of soluble CD4 (American Biotechnologies, Columbia, MD) to compete with Fab fragments for gpl20 coated on ELISA wells was carried out using similar procedures.
Estimation ofFab Concentrations in Supernatants. This was carried out by sandwich ELISA (26) .
Purification of Fabs. One-liter cultures of E. coli in super broth (23) containing carbenicillin (50 pug/ml) and MgCl2 (20 mM) were inoculated with appropriate clones, induced 7 hr later with 2 mM isopropyl P-D-thiogalactopyranoside, and grown overnight at 30"C. The cell pellets were sonicated and the supernatant was concentrated to 50 ml. The filtered supernatants were loaded on a 25-ml protein G-anti-Fab column, washed with 120 ml ofbuffer at 3 ml/min, and eluted with citric acid at pH 2.3. The neutralized fractions were then concentrated, exchanged into 50 mM Mes (pH 6.0), and loaded onto a 2-ml Mono S column (Pharmacia) at 1 ml/min. A gradient of 0-500 mM NaCl was run at 1 ml/min, and the Fab fragments were eluted in the range of 200-250 mM NaCl. After concentration, the Fab fragments were positive when titered by ELISA against gpl20 and gave a single band at 50 kDa by SDS/10-15% PAGE. Concentration was determined from absorbance measurement at 280 nm by using an extinction coefficient (1 mg/ml) of 1. generally repeated at least twice with reproducible results. For the data reported in Table 1 , the Fab supernatants were divided into two parts, one being used in the p24 assay and the other in the syncytium assay. Table 1 shows that two Fab fragments, 4 and 12, are effective neutralizers in both types of assay. These Fab fragments have also been shown to neutralize infection by IIIB and RF strains in a PCR-based assay of proviral integration (L. Montaner, S. Gordon, C. F. B., and D. R. B., unpublished work). Fab 13 is consistently effective in the p24 assay but not in the syncytium assay. A number of other clones show lower levels of neutralizing ability.
Fab fragments were purified from a selection of some ofthe clones and used in both neutralization assays. As shown in Fig. 1 , Fab fragments 4 and 12 are again effective in both assays at similar levels, with, for example, 50o inhibition of syncytium formation at an Fab concentration of -20 nM (1 jug/ml). Fab fragments 7 and 21 are equally as effective in the syncytium assay but somewhat less so in the p24 assay. Fab 13 neutralizes in the p24 assay at 4 ,ug/ml but is ineffective in the syncytium assay at 25 jug/ml. Grop 1 Proc. Natl. Acad. Sci. USA 89 (1992) 9341 A number of conclusions arise from the data of Table 1 and Fig. 1 . It is apparent that HIV-1 can be neutralized without virion aggregation or crosslinking of gpl20 molecules on the virion surface, since monovalent Fab fragments are effective. To further confirm this finding we generated an Fab fragment by papain digestion of a known neutralizing human monoclonal antibody. As shown in Table 1 , the Fab fragment was approximately equally effective as the whole IgG in neutralization of the MN strain of HIV-1. This is consistent with results on Fab fragments prepared from two mouse monoclonal antibodies to the V3 loop (M. Merges and P. L. N., unpublished work). An F(ab')2 fragment of a mouse monoclonal antibody was somewhat less effective than the parent IgG in neutralization of the MN strain. Interestingly the fragments from these control antibodies were relatively poor in neutralizing the IIIB strain of HIV-1. Table 1 and Fig. 1 also show that there appears to be a difference between the two assays employed, since Fab 13 is consistently effective in one assay but not the other. The principal variables are the incubation time of the virus and antibody prior to infection (2 hr for the p24 assay and 0.5 hr for the syncytium assay), the amount of virus used for infection, the cells used to propagate virus (human PBMCs for the former and H9 cells for the latter), and the cells infected (human PBMCs for the former and CEM.SS cells for the latter). Of these, there is a strong possibility that the MN virus used in the two assays, having been passaged through different cells, is critically different.
To explore the relationship between neutralizing and weakly or nonneutralizing Fabs, the variable domains of the 20 clones were sequenced. A detailed comparison of the sequences will be provided elsewhere (C. . Sanz, and D.R.B., unpublished work). The heavy-chain sequences can be organized into six groups where each member of a group has an identical or very similar third complementarity-determining region, with a limited number of differences elsewhere. When the light chains are constrained into the groupings defined by their heavy-chain partners, considerable light-chain sequence variation is observed. This phenomenon of chain promiscuity has been observed previously (22, (33) (34) (35) (36) 
